ENSEM Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
200 Boston Ave Ste 1875, Medford, Massac...Phone Number
(781) 874-2500Website
www.ensemtx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About ENSEM Therapeutics
Headquartered in Boston, MA, ENSEM Therapeutics is a biotechnology company with a focus on oncology targets.Explore more
ENSEM Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ENSEM Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
ENSEM Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at ENSEM Therapeutics
Check if ENSEM Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once ENSEM Therapeutics has new funding data
Click to see if ENSEM Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when ENSEM Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Check out if ENSEM Therapeutics is spiking on competitors!
Earning: See what the market has to say on ENSEM Therapeutics recently announced quarterly report
Recommended Actions
Find VP level buyers at ENSEM Therapeutics
Find 3 more new buyers
Compare Similar Companies to ENSEM Therapeutics
Compare insights from companies similar to ENSEM Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ENSEM Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ENSEM Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ENSEM Therapeutics.
ENSEM Therapeutics financials insights
Gather financial insights about ENSEM Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$67M
ENSEM Therapeutics Tech Stack
A closer look at the technologies used by ENSEM Therapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Promotion
Executive Move
New Hire
Executive Move
Michael Haley has joined the organization as Vice President, Human Resources.
Executive Moves, New Hire
Funding
ENSEM Therapeutics News & Media
Ensem Therapeutics Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble® platform to advance innovative small molecule precision medicines for oncology, today announced that Dr. Shengfang Jin, Chief Executive Officer of ENSEM, will present an overview of the company and its pipeline progress at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 7:30 a.m. PT/ 10:30 a.m. ET. AEnsem Therapeutics To Present Preclinical Data for Potential Best-in-Class Oral CDK2 Inhibitor at San Antonio Breast Cancer Symposium
WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble® platform to advance innovative small molecule precision medicines for oncology, will report for the first time preclinical data on ETX-197/BG-68501, a potential best-in-class oral, selective CDK2 inhibitor at the 47th Annual San Antonio Breast Cancer Symposium (“SABCS”) in San Antonio, Texas. ETX-197/BG-68501 has a differentiated precEnsem Therapeutics To Present Preclinical Data for Potential Best-in-Class Allosteric Pan-Mutant-Selective PI3Kα Inhibitor and Degrader at San Antonio Breast Cancer Symposium
WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble® platform to advance innovative small molecule precision medicines for oncology, today announced the first presentation of preclinical data on ETX-636, a potential best-in-class novel allosteric pan-mutant-selective PI3Kα inhibitor and degrader. ETX-636 has a differentiated preclinical profile and the potential to deliver clinical beneEnsem Therapeutics Announces Achievement of Milestone Following Entry of Small Molecule CDK2 Inhibitor into Clinical Trials for Solid Tumors
WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. today announced that its partner BeiGene has dosed the first five patients in its first-in-human Phase 1 trial to evaluate BG-68501, a small molecule cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of solid tumors. The achievement triggers a milestone payment from BeiGene, which licensed the compound (formerly ETX-197) from ENSEM in November 2023. BG-68501 is the first clinical stage compound to emerge from ENSEM’s Kinetic E
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ENSEM Therapeutics
Sign Up For FreeTo access detailed company insights
Headquartered in Boston, MA, ENSEM Therapeutics is a biotechnology company with a focus on oncology targets.... Read More
